Chemical industry – Page 86
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
US turnaround on Avandia restrictions
Researchers accuse regulator of face-saving U-turn over diabetes medication safety
-
Opinion
Unwelcome festive offerings
It’s not easy to learn you’re going to lose your job, especially at this time of year
-
OpinionPut the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
BusinessReach is a big trade barrier, say US manufacturers
Europe says requirements for US companies are the same as for EU competitors
-
FeatureFarming tomorrow
Technology is helping farmers better control the use of fertilisers and pesticides, as Elisabeth Jeffries reports
-
Business
Regulator cracks down on 23andMe
Personal genetic profiler ordered to stop selling DNA test kits
-
Business
Pfizer teams up with GSK in cancer drug trial
Two companies will collaborate to develop a combination therapy for melanoma
-
FeatureGeneric problems
The Indian pharmaceutical industry has been hit by recent problems. Angeli Mehta investigates
-
Business
DSM to spin out pharma unit
Firm will combine with Patheon to provide manufacturing services
-
BusinessRapid DNA sequencing cleared for the clinic
Illumina’s ‘next-generation’ MiSeqDx platform gets US approval
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
-
CareersThe pain killer
Life is pretty painless working in Reckitt Benckiser’s Nurofen team, Sarah Houlton learns
-
BusinessFracking risks are manageable, says UK industry body
Environmental impact of shale gas exploration should be minimal with proper oversight
-
Business
Shire will cut UK R&D to focus on rare diseases
$4.2bn buyout of ViroPharma bolsters pipeline, while Basingstoke site halts research
-
BusinessMis-selling lands J&J with $2.2bn fine
Company found guilty of promoting three drugs for unapproved uses
-
Business
Japanese chemicals show signs of recovery
Reconstruction after 2011 disaster drives higher demand
-
Business
Novartis to shut Horsham site
UK research centre closure to result in the loss of 371 jobs as firm consolidates its global R&D base
-
